Staging of patients after extrapleural pneumonectomy for malignant pleural mesothelioma - institutional review and current update

Interactive Cardiovascular and Thoracic Surgery

Volumn 12, Issue 5, 2011, Pages 756-

  Cao, Christopher ^a,b   Andvik, Sarah Karen Krog ^a,b   Yan, Tristan D ^a,b   Kennedy, Catherine ^a,b   Bannon, Paul G ^a,b   McCaughan, Brian C ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b The Baird Institute Australia   (Australia)

Author keywords

Extrapleural pneumonectomy; Malignant pleural mesothelioma; Staging

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BRONCHOPLEURAL FISTULA; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; EMPYEMA; EXTRAPLEURAL PNEUMONECTOMY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEMATOTHORAX; HUMAN; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PLEURA MESOTHELIOMA; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROGNOSIS; SEPSIS; SURVIVAL RATE; VOCAL CORD PARALYSIS;

EID: 79956220902     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1510/icvts.2010.262972     Document Type: Article

References (15)

1. Ruffie P, Feld R, Minkin S, Cormier Y, Boutan-Laroze A, Ginsberg R, Ayoub J, Shepherd FA, Evans WK, Figueredo A, Pringle JF, Kreisman H. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989;7:1157-1168.
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
3. Cao CQ, Yan TD, Bannon PG, McCaughan BC. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 2010;5:1692-1703.
4. Butchart EG, Ashcroft T, Barnsley WC, Holden MP. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976;31:15-24.
5. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108:1122-1128.
6. Sugarbaker DJ, Strauss GM, Lynch TJ, Richards W, Mentzer SJ, Lee TH, Corson JM, Antman KH. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993;11:1172-1178.
7. Travis W, Brambilla E, Müller-Hermelink H, Harris C. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon, France: IARC Press, 2004.
8. Flores RM, Akhurst T, Gonen M, Zakowski M, Dycoco J, Larson SM, Rusch VW. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2006;132:763-768.
9. Edwards JG, Martin-Ucar AE, Stewart DJ, Waller DA. Right extrapleural pneumonectomy for malignant mesothelioma via median sternotomy or thoracotomy? Short- and long-term results. Eur J Cardiothorac Surg 2007;31:759-764.
10. Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996;111:815-825.
11. Flores RM, Zakowski M, Venkatraman E, Krug L, Rosenzweig K, Dycoco J, Lee C, Yeoh C, Bains M, Rusch V. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007;2:957-965.
12. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, Bains MS, Downey RJ, Ginsberg RJ. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788-795.
13. Richards WG, Godleski JJ, Yeap BY, Corson JM, Chirieac LR, Zellos L, Mujoomdar A, Jaklitsch MT, Bueno R, Sugarbaker DJ. Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. Cancer 2010;116:1510-1517.
14. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, Baldini EH, Mentzer SJ. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63; discussion 63-55.
15. de Perrot M, Feld R, Cho BCJ, Bezjak A, Anraku M, Burkes R, Roberts H, Tsao MS, Leighl N, Keshavjee S, Johnston MR. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:1413-1418.